Metastasis to para-aortic lymph nodes cephalad to the renal veins in patients with ovarian cancer.
Adult
Aged
Aorta, Abdominal
Carcinoma, Ovarian Epithelial
/ pathology
Fallopian Tube Neoplasms
/ pathology
Female
Humans
Lymph Node Excision
Lymph Nodes
/ pathology
Lymphatic Metastasis
Middle Aged
Ovarian Neoplasms
/ pathology
Pelvis
/ pathology
Peritoneal Neoplasms
/ pathology
Renal Veins
/ pathology
Retrospective Studies
Epithelial ovarian cancer
Extended PAN dissection
FIGO stage
Supra-renal para-aortic node metastasis
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
01 Apr 2020
01 Apr 2020
Historique:
received:
03
12
2019
accepted:
19
03
2020
entrez:
3
4
2020
pubmed:
3
4
2020
medline:
16
12
2020
Statut:
epublish
Résumé
In patients with epithelial ovarian cancer, whether metastasis to para-aortic lymph nodes located cephalad to the renal veins (supra-renal PAN) should be classified as regional lymph node metastasis or distant metastasis remains controversial. This study was a preliminary retrospective evaluation of the pattern of supra-renal PAN metastasis in patients with epithelial ovarian cancer. The subjects were 25 patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who underwent systematic dissection of the para-aortic nodes, including the supra-renal PAN, and pelvic lymph nodes (PLN). Patient factors, perioperative factors, the number of dissected lymph nodes, and pathological lymph node metastasis were investigated. Supra-renal PAN metastasis was found in 4/25 patients (16.0%). None of the 14 patients with pT1 or pT2 disease had supra-renal PAN metastasis, while 4/11 patients (36.4%) with pT3 or ypT3 disease had such metastases. None of the patients had isolated supra-renal PAN metastasis, while patients with supra-renal PAN metastasis also had multiple metastases to the infra-renal PAN and PLN. In patients with epithelial ovarian cancer, supra-renal PAN metastases might be considered to be distant rather than regional metastases. Further studies are needed to better define the clinical significance of supra-renal PAN metastasis.
Sections du résumé
BACKGROUND
BACKGROUND
In patients with epithelial ovarian cancer, whether metastasis to para-aortic lymph nodes located cephalad to the renal veins (supra-renal PAN) should be classified as regional lymph node metastasis or distant metastasis remains controversial. This study was a preliminary retrospective evaluation of the pattern of supra-renal PAN metastasis in patients with epithelial ovarian cancer.
METHODS
METHODS
The subjects were 25 patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who underwent systematic dissection of the para-aortic nodes, including the supra-renal PAN, and pelvic lymph nodes (PLN). Patient factors, perioperative factors, the number of dissected lymph nodes, and pathological lymph node metastasis were investigated.
RESULTS
RESULTS
Supra-renal PAN metastasis was found in 4/25 patients (16.0%). None of the 14 patients with pT1 or pT2 disease had supra-renal PAN metastasis, while 4/11 patients (36.4%) with pT3 or ypT3 disease had such metastases. None of the patients had isolated supra-renal PAN metastasis, while patients with supra-renal PAN metastasis also had multiple metastases to the infra-renal PAN and PLN.
CONCLUSIONS
CONCLUSIONS
In patients with epithelial ovarian cancer, supra-renal PAN metastases might be considered to be distant rather than regional metastases. Further studies are needed to better define the clinical significance of supra-renal PAN metastasis.
Identifiants
pubmed: 32238145
doi: 10.1186/s12957-020-01841-8
pii: 10.1186/s12957-020-01841-8
pmc: PMC7114794
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
64Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP18K09302
Références
Int J Gynecol Cancer. 2009 Nov;19(8):1307-13
pubmed: 20009882
J Natl Cancer Inst. 2005 Apr 20;97(8):560-6
pubmed: 15840878
Ann Surg Oncol. 2012 Oct;19(11):3522-7
pubmed: 22644507
Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1238-44
pubmed: 17433064
Gynecol Oncol. 2017 May;145(2):407-408
pubmed: 28237617
N Engl J Med. 2019 Feb 28;380(9):822-832
pubmed: 30811909
J Clin Oncol. 2010 Apr 1;28(10):1733-9
pubmed: 20194855
J Surg Oncol. 2017 Sep;116(3):329-336
pubmed: 28542980
Gynecol Oncol. 2011 Dec;123(3):610-4
pubmed: 21982047
Ann Surg Oncol. 2016 Apr;23(4):1279-86
pubmed: 26832880
Int J Clin Oncol. 2003 Aug;8(4):248-75
pubmed: 12955581
J Gynecol Oncol. 2018 Jan;29(1):e12
pubmed: 29185270
Int J Gynaecol Obstet. 2014 Jan;124(1):1-5
pubmed: 24219974